Frisius
- Address
- lock Available on a paid plan
Frisius Vision Research Center
Frisius is a specialized research center dedicated to advancing the understanding and treatment of pediatric vision disorders, with particular expertise in progressive myopia in children. The center focuses on developing evidence-based interventions to address the growing global concern of childhood myopia progression.
- Comparative efficacy studies of atropine concentrations for myopia control
- Pediatric ophthalmology and refractive error management
- Safety and adherence evaluation in long-term vision therapies
The research team at Frisius conducts rigorous clinical trials examining pharmacological interventions for myopia progression, specifically evaluating different atropine dosing strategies in European pediatric populations. Their work addresses critical questions regarding treatment optimization, patient safety, and factors influencing therapeutic response in children with progressive myopia.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 24 therapeutic areas and 15 of 265 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 261 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 30 by active trials.
lock +29 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +17 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Frisius
lock Showing 1 of 115 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Randomized Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma | Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting | Phase II | Not Recruiting | Nov 2018 | — |
IMP list
lock Showing 1 of 265 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Oxaliplatin | 14 | Unknown | 2017-09-28 | 2026-05-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.